Now Ocrevus blocked from health service in Scotland

Hot on the heels of NICE rejecting Ocrevus (ocrelizumab) as a treatment of PPMS by the National Health Service (NHS) in England, it has been blocked as a therapy for relapsing MS in Scotland. The Scottish Medicines Consortium (SMC) says it does not consider ocrelizumab to be cost effective for the NHS in Scotland  as a treatment … Continue reading Now Ocrevus blocked from health service in Scotland

MS drug Ocrevus could be barred from health service

Ocrevus may have taken the worldwide multiple sclerosis community by storm but it seems set for a rocky ride in the United Kingdom. It’s quite possible that it will not be available through the country’s National Health Service (NHS). Although the drug1, known by the non-brand name, ocrelizumab, was licensed by the European Medicines Agency … Continue reading MS drug Ocrevus could be barred from health service

Drug ´breakthrough´ for primary progressive MS

Everyone living with primary progressive multiple sclerosis should be excited by the fact a drug being developed for treatment of that particular type of MS has been given ´breakthrough´ designation by the USA´s Food and Drug Administration (FDA). The special status means that the drug, called ocrelizumab, could be approved more quickly following positive phase … Continue reading Drug ´breakthrough´ for primary progressive MS